Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for moderate-to-severe plaque psoriasis. The double-blind, placebo-controlled ...

Paris, France, February 20, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...

NKGen Biotech (NKGN) announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator for its Phase 2a clinical ...

Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...

As a Clinical Research Coordinator, she has overseen several Phase 2a trials, focusing on the efficacy of novel treatments and ensuring that all regulatory requirements are met. Her medical ...

This collaboration will focus on patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 2a clinical trial. The trial aims to explore the dual-targeting ...

in Immuneering’s ongoing Phase 2a clinical trial of IMM-1-104 in advanced solid tumors. “We are excited to announce this collaboration, which is the first that Immuneering has entered with IMM-1-104.